Skip to search formSkip to main contentSkip to account menu

sifalimumab

Known as: Immunoglobulin G1, Anti-(Human Interferon Alpha) (Human Monoclonal MEDI-545 Heavy Chain), Disulfide with Human Monoclonal MEDI-545 Alpha-Chain, Dimer, MDX 1103, MEDI 545 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
I9 Clinical trials with IFN blockers
Background Type I interferon (IFN) pathway activation has long been demonstrated in patients with systemic lupus erythematosus… 
2019
2019
Efficacy of sifalimumab for treatment of skin injury caused by systemic lupus erythematosus
Abstract Background: This study aims to provide the best possible evidence-based information on the efficacy and safety of… 
2018
2018
Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation
Oligonucleotide overloading results in type I interferonopathies such as the Aicardi-Goutiéres Syndrome, a progressive… 
2018
2018
Faculty Opinions recommendation of Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
  • M. Bertolaccini
  • Faculty Opinions – Post-Publication Peer Review…
  • 2018
  • Corpus ID: 81640607
Review
2017
Review
2017
Additional Improvements in Clinical Response From Adjuvant Biologic Response Modifiers in Adults With Moderate to Severe Systemic Lupus Erythematosus Despite Immunosuppressive Agents: A Systematic…
Review
2016
Review
2016
Why, why, why de-lupus (does so badly in clinical trials)
There is abundant evidence that B-lymphocytes play a major role in the development of lupus (reviewed in [1]). It thus seemed… 
Review
2016
Review
2016
OP0044 Systemic Lupus Erythematosus (SLE) Responder Index [SRI(4)] Response Is Associated with Global Benefit in Patients with Moderate To Severe SLE
Background The SRI(4) is a composite endpoint used in SLE clinical trials. A post-hoc analysis of two Phase III studies of… 
2015
2015
AB0167 Pharmacokinetics of Sifalimumab and Target Modulation of a Type I Interferon Gene Signature in Patients with Moderate to Severe Systemic Lupus Erythematosus
Background Sifalimumab is a fully human, IgG1κ monoclonal antibody in Phase IIb clinical development for systemic lupus… 
2015
2015
AB0183 The Effect of Geography on the Efficacy of Sifalimumab, an Anti-Interferon-Alpha Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus
Background The efficacy and safety of sifalimumab were assessed in a Phase IIb, randomized, double-blind, placebo-controlled… 
2015
2015
AB0189 Geographic Differences in Demographics, Clinical Characteristics, and Standard of Care in Multinational Studies of Patients with Moderate to Severe Sle
Background Most randomized controlled clinical trials (RCTs) in systemic lupus erythematosus (SLE) include stratification factors… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)